BioCentury
ARTICLE | Top Story

Biogen's anti-LINGO-1 mAb fails Phase II test

June 8, 2016 1:06 AM UTC

Biogen Inc. (NASDAQ:BIIB) fell $36.98 (13%) to $252.86 on Tuesday after reporting that opicinumab ( BIIB033) plus Avonex interferon beta-1a missed the primary endpoint vs. placebo plus Avonex in the Phase II SYNERGY study to treat relapsing forms of multiple sclerosis, including relapsing-remitting MS and secondary progressive MS. Opicinumab is a mAb against leucine-rich repeat neuronal protein 1 ( LINGO-1).

The primary endpoint evaluated the proportion of patients with a three-month improvement across four measures: ambulation as measured by the timed 25-foot walk (TW25) test; upper extremity function as evaluated by the 9-hole peg test; cognition as evaluated by the 3-second paced auditory serial addition test; and disability as measured by Expanded Disability Status Scale (EDSS) scores. ...